340B and Overprescription

A recent study out of the University of California, San Francisco, reveals that breast cancer patients at entities participating in the 340B program are 25% more likely to be prescribed outpatient drugs. The intensity of this treatment rose by 40% when dispensed by a covered entity, however, there is no found evidence of improved patient survival.

The 340B program consistently makes substantial profits on outpatient drugs and discourages treatments that would limit the necessity of outpatient drugs. 340B hospital systems often use these profits to expand into wealthy neighborhoods, leaving vulnerable populations behind. Our Health Equity opposes the expansion of the 340B program and advocates for reforms that would put patients over profits. Read more here.